Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephen Moore | M | 59 | 10 years | |
| Salvatore Salibello | M | 78 | 4 years | |
| David L. Clark | M | 70 |
Prolexys Pharmaceuticals, Inc.
 Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 19 years |
| Marc Gabelli | M | 56 | 7 years | |
| Kimberly V. Rogers | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 20 years |
| Chad Bello | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 22 years |
| Robert R. Becklin | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 22 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gregg Engles | M | 65 | 18 years | |
| Gregg A. Tanner | M | 67 | 10 years | |
| Rachel Gonzalez | F | 54 | 6 years | |
| Gary Sugarman | M | 71 | 15 years | |
| Michelle Goolsby | F | 66 | 10 years | |
| Scott Vopni | M | 55 | 11 years | |
| Daniel E. Hopkins | M | - | 1 years | |
| J. Wayne Mailloux | M | 75 | 11 years | |
| Kent Misener | M | 72 |
Utah State University
| 6 years |
| Brian Clement Israelsen | M | - |
Utah State University
| 5 years |
| V. Kelly Randall | M | 73 |
Utah State University
| 6 years |
| C. Shay Braun | M | 56 | 9 years | |
| Kimberly Warmbier | F | 62 | 5 years | |
| Donald Hunter | M | 67 | 1 years | |
| Joseph Scalzo | M | 65 | 6 years | |
| Shaun Mara | M | 60 | 3 years | |
| Hui Tang | F | 64 |
Utah State University
| 6 years |
| Doreen A. Wright | F | 67 | 4 years | |
| Sherri Baker | F | 51 | 2 years | |
| Liliana Esposito | F | 49 | 4 years | |
| Rick Collins | M | - |
Utah State University
| 6 years |
| Jay Dee Clayton | M | 71 |
Utah State University
| 4 years |
| Gar Forman | M | - |
Utah State University
| 4 years |
| Kent R. van Kampen | M | - |
Utah State University
| 4 years |
| Robert Irvin | M | - |
Utah State University
| 4 years |
| Timothy Burns | M | 49 | 9 years | |
| Thomas N. Zanetich | M | 72 | - | |
| Kelly Duffin-Maxwell | F | 59 | - | |
| Matthew Favre | M | - | - | |
| Gregory McKelvey | M | 51 | 7 years | |
| Rick L. Johnson | M | 70 |
Utah State University
| 4 years |
| Abdul Hapiz bin Abdullah | M | 66 |
Utah State University
| 3 years |
| Sanah Marah | M | 46 | 4 years | |
| Jose A. Motta | M | 59 | 7 years | |
| Michael Nathenson | M | 60 | 3 years | |
| Carrie Tharp | F | 43 | 3 years | |
| Wesley D. Bigler | M | - |
Utah State University
| 4 years |
| Don A. Tanner | M | - |
Utah State University
| 4 years |
| Daren Shaw | M | 67 |
Utah State University
| 4 years |
| Edward F. Fugger | M | 56 | 8 years | |
| Rachel P. Cullen | F | 65 | 5 years | |
| Andy Smith | M | - |
Utah State University
| 7 years |
| Trisha L. Fox | F | 54 | 2 years | |
| Jerrold N. Mayer | M | - |
Utah State University
| 1 years |
| Steven McDowell | M | 62 | 6 years | |
| Brian Murphy | M | 56 | - | |
| Richard Gillis | M | - | - | |
| Richard Zuroweste | M | - | - | |
| James F. Kohler | M | 76 |
Utah State University
| 1 years |
| Joseph H. Gardner | M | 68 |
Utah State University
| 1 years |
| John Callahan | M | 66 | 4 years | |
| Ronald Kirk | M | 69 | 6 years | |
| Melinda Scissors Conley | F | 58 | 5 years | |
| Rory Lee Miller | M | 63 |
Utah State University
| 4 years |
| Christopher D. Sliva | M | 60 | 6 years | |
| Gary M. Julien | M | 54 | - | |
| Paul T. Moskowitz | M | 60 | 4 years | |
| Ronald L. McCrummen | M | 59 | 6 years | |
| Pete Schenkel | M | 88 | 9 years | |
| Ronald H. Klein | M | 58 | 7 years | |
| Elliott N. Taylor | M | 65 |
Utah State University
| 4 years |
| Kenneth C. Johnsen | M | 65 |
Utah State University
| 4 years |
| E. Heiner | M | 62 |
Utah State University
| 6 years |
| John S. Llewellyn | M | 89 | 6 years | |
| Lewis Collens | M | 88 | 8 years | |
| Alan J. Bernon | M | - | 11 years | |
| Jonathon Bunker | M | 64 |
Utah State University
| 4 years |
| Gary E. Stevenson | M | 68 |
Utah State University
| 4 years |
| Bryce M. Petersen | M | - |
Utah State University
| 4 years |
| Deborah B. Carosella | F | 67 | - | |
| Alan K. Smith | M | 68 |
Utah State University
| 7 years |
| Harrald F. K. Kroeker | M | 66 | 4 years | |
| William A. Swanston | M | 70 | 3 years | |
| Bradly A. Oldroyd | M | - |
Utah State University
| 4 years |
| Robert K. Reynolds | M | - |
Utah State University
| 4 years |
| Christopher Bellairs | M | 63 | 9 years | |
| Leland George Foster | M | 78 |
Utah State University
| 4 years |
| Thomas D. Ingolia | M | 71 |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | - |
| Eric Harrison Edwards | M | 68 |
Utah State University
| 4 years |
| James DaBramo | M | 65 | 6 years | |
| Prasert Bunsumpun | M | 72 |
Utah State University
| 2 years |
| Scott R. Watterson | M | 68 |
Utah State University
| 4 years |
| Barbara D. Carlini | F | 63 | 4 years | |
| Avrum Gray | M | 88 | - | |
| Andrew Judd | M | - | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 92 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- John M. Aoki
- Personal Network
